• Multiple Myeloma — An Interview with Dr Surbhi Sidana on Optimizing the Role of CAR T-Cell Therapy

  • 2025/02/19
  • 再生時間： 47 分
  • ポッドキャスト

Multiple Myeloma — An Interview with Dr Surbhi Sidana on Optimizing the Role of CAR T-Cell Therapy

無料で聴く

ポッドキャストの詳細を見る

  • サマリー

  • Featuring an interview with Dr Surbhi Sidana, including the following topics:

    • Long-term outcomes for patients with relapsed/refractory multiple myeloma (MM) (0:00)
    • Clinical considerations in the selection of patients for chimeric antigen receptor (CAR) T-cell therapy (3:34)
    • Practical challenges for patients receiving CAR T-cell therapy (8:34)
    • Selection among available CAR T-cell therapies (12:18)
    • Prevention, management and supportive care involved in the management of toxicities associated with CAR T-cell therapy (16:34)
    • Secondary cancers associated with CAR T-cell therapy (21:25)
    • Bridging therapy considerations for patients receiving CAR T-cell treatment (25:15)
    • Utility of antibody-drug conjugates and bispecific antibodies for MM (27:49)
    • Case: A man in his early 40s experiences rapid progression on induction therapy for MM (31:59)
    • Case: A man in his early 50s with heavily pretreated MM receives multiple CAR T-cell therapies (41:47)

    CME information and select publications
    続きを読む 一部表示

あらすじ・解説

Featuring an interview with Dr Surbhi Sidana, including the following topics:

  • Long-term outcomes for patients with relapsed/refractory multiple myeloma (MM) (0:00)
  • Clinical considerations in the selection of patients for chimeric antigen receptor (CAR) T-cell therapy (3:34)
  • Practical challenges for patients receiving CAR T-cell therapy (8:34)
  • Selection among available CAR T-cell therapies (12:18)
  • Prevention, management and supportive care involved in the management of toxicities associated with CAR T-cell therapy (16:34)
  • Secondary cancers associated with CAR T-cell therapy (21:25)
  • Bridging therapy considerations for patients receiving CAR T-cell treatment (25:15)
  • Utility of antibody-drug conjugates and bispecific antibodies for MM (27:49)
  • Case: A man in his early 40s experiences rapid progression on induction therapy for MM (31:59)
  • Case: A man in his early 50s with heavily pretreated MM receives multiple CAR T-cell therapies (41:47)

CME information and select publications
続きを読む 一部表示
activate_buybox_copy_target_t1

Multiple Myeloma — An Interview with Dr Surbhi Sidana on Optimizing the Role of CAR T-Cell Therapyに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。